FGFR2 and neoplasm: This data raises the possibility that patients with MMRd ECs their tumour harbouring oncogenic FGFR2 activation by isoform switching may not benefit from the recently reported chemotherapy plus immunotherapy combinations39,40 due to intrinsic chemotherapy resistance.